Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
EWTX Stock Chart & Stats
$21.74
-$0.39(-1.54%)
At close: 4:00 PM EST
$21.74
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$10.60 - $30.48
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.63M
Market Cap
$2.89B
Enterprise Value$1.15B
Total Cash (Recent Filing)$563.34M
Total Debt (Recent Filing)$4.18M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Feb 19, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding105,868,430
10 Day Avg. Volume2,501,540
30 Day Avg. Volume1,629,538
Financial Highlights & Ratios
PEG Ratio2.41
Price to Book (P/B)5.37
Price to Sales (P/S)0.00
P/FCF Ratio-22.36
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.68
Forecast
1Y Price Target
$37.63Price Target Upside73.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2 CIRRUS-HCM Part D trial has achieved strong enrollment, indicating progress in cardiac programs.
Drug DevelopmentSevasemten has the potential to become the first approved drug for Becker muscular dystrophy, offering a new treatment option for this condition.
Financial PositionEdgewise ended the quarter financially strong with $563.3 million in cash.
Bears Say
Market ReactionShares dropped -33% as investors expressed concerns on the rates of atrial fibrillation (AFib) and potential differentiation versus competing cardiac myosin inhibitors (CMIs).
Regulatory ChallengesFollowing the 3Q25 update, analyst is cutting sevasemten DMD estimates as there is a challenging regulatory/competitive backdrop likely taking greater time to resolve.
Safety ConcernsEWTX reported an additional new-onset afib case in Part D, which raises ongoing safety concerns that cannot be resolved without long-term data.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $10.60 and its highest was $30.48 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $2.89B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 55 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.007.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 105,868,430 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went down -1.612%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.63 (73.09% Upside)
$37.63 (73.09% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.46%
12-Months-Change
Fundamentals
Return on Equity
-30.02%
Trailing 12-Months
Asset Growth
14.12%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$37.63
▲(73.09% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
1.39% Insiders
11.37% Mutual Funds
75.37% Other Institutional Investors
3.35% Public Companies and
Individual Investors